OnCall cover art

All Episodes

OnCall — 57 episodes

#
Title
1

Q1 2026 GPO Legislative Townhall

2

Operationalizing Radiopharmaceuticals in Your Practice

3

Radiopharmaceuticals: Billing and Reimbursement

4

Radiopharmaceutical Landscape

5

Introduction to Radiopharmaceuticals

6

Q4 2025 GPO Legislative Townhall

7

Q3 GPO Legislative Townhall

8

Inflation Reduction Act: Current State

9

Q2 GPO Legislative Townhall

10

Inflation Reduction Act: Overview

11

505(b)(2) Operationalizing in Practice - Provider Perspective

12

505(b)(2) Operationalizing in Practice - Pharmacist Perspective

13

505(b)(2) Billing and Reimbursement

14

505(b)(2) Landscape and Pipeline

15

505(b)(2) Basics

16

Buy and Bill: Practice Perspective

17

Buy and Bill: The Basics

18

GPO 101: Legislative Townhall

19

Biosimilar Basics: Payer Perspective

20

Biosimilar Basics: Legislation

21

Biosimilar Basics: Market Landscape

22

Biosimilar Basics: Overview

23

GPO Legislative Townhall December 2023: Part 11

24

GPO Legislative Townhall December 2023: Part 10

25

GPO Legislative Townhall December 2023: Part 9

26

GPO Legislative Townhall August 2023: Part 8

27

GPO Legislative Townhall August 2023: Part 7

28

GPO Legislative Townhall May 2023: Part 6

29

GPO Legislative Townhall May 2023: Part 5

30

GPO Legislative Townhall May 2023: Part 4

31

GPO Legislative Townhall Feb 2023: Part 3

32

GPO Legislative Townhall Feb 2023: Part 2

33

GPO Legislative Townhall Feb 2023: Part 1

34

Operational Pathways for Biomarker Testing in NSCLC

35

Biosimilar Series: Part 5

36

Biosimilar Series: Part 4

37

Biosimilar Series: Part 3

38

Biosimilar Series: Part 2

39

Biosimilar Series: Part 1

40

Biomarkers: Emerging Targets and Technologies

41

Biomarker Testing: A Closer Look at When, Who, and How to Test

42

Germline Genetic Testing

43

Buy and Bill 101: Part 4

44

Buy and Bill 101: Part 3

45

Biomarkers 101: Basics of Biomarker Testing

46

Buy and Bill 101: Part 2

47

Buy and Bill 101: Part 1

48

Novel Agents and Toxicity Management 101

49

Using AI Clinical Decision Support to Manage Cancer Complexity

50

Paradigms, Policy and Pharmacogenomics: What community oncologists need to know

51

Clinical trials: How has precision medicine elevated the role of community oncology?

52

Treating with TIBSOVO: A targeted therapeutic option for patients with R/R mIDH1 AML

53

Off Our Chests: A Discussion with Dr. John and Liza Marshall

54

Precision Medicine Series: Evolution Part 2

55

Precision Medicine Series: Evolution Part 1

56

A Conversation with Annexus Health

57

Precision Medicine Series: Precision Medicine Center